<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596334</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO 2015-03</org_study_id>
    <nct_id>NCT02596334</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients</brief_title>
  <acronym>MONCAY</acronym>
  <official_title>Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay®) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq®) in HIV-1- Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple antiretroviral regimens have greatly improved the prognosis of patients living with
      HIV (PLHIV). Patients virologically controlled and having a good immune restoration can have
      a life expectancy close or equal to that of people not infected with HIV.[1] However, this is
      under the condition of a &quot;lifetime&quot; maintenance of an undetectable plasma viral load (pVL)
      (&lt;50 cp/ml). On the other hand it is well established that aging increases comorbidities
      among PLHIV and the burden of co-medications.[2] This also has the consequence of frequent
      drug-drug interactions. In this context it is important to decrease pills burden,
      side-effects and drug-drug interactions, while maintaining undetectability.

      Currently, there is a strong interest for medical research to validate lightened regimens
      (i.e. bithérapies [3-7] and monothérapies [8,9], particularly in a maintenance strategy, with
      the primary objective of reducing burden of pills and side effects. Several monotherapy
      trials using a boosted protease inhibitor (PI/r) showed high level of viral suppression, even
      if this proportion was not always non-inferior to maintaining a triple therapy. [8,9]
      Fortunately, when virological failure occurred under monotherapy virologic suppression was
      easily restored by the addition of two NRTI. Patients who are most likely to maintain viral
      suppression under a reduced scheme are those that have a high nadir (&gt; 100 CD4 / mm3), no
      previous AIDS event and a sustained virologic suppression (&gt;12 months).

      Monotherapy is the option that best reduces the burden of pills and the risk of side effects
      or drug-drug interactions. It must be considered using very powerful molecule that harbor a
      strong binding to its ligand in order to minimize the risk of selecting resistant mutants in
      the case of virologic failure. To be as simple as possible in its use, it must be a single
      agent administered as a single dose once a day and not boosted if possible. The molecule must
      have very good tolerance. Finally, to be effective in viral sanctuaries this molecule should
      have a good (or sufficient) diffusion to ensure effective Cmin on wild viral strains.
      Dolutegravir meets all these exigences.[10] In addition, our team recently presented results
      of a pilot study showing that the switch of a successful combined antiretroviral regimen to
      dolutegravir monotherapy maintained undetectable viral load (&lt;20 cp/ml) after a median of 7
      months (range 6.5-10 months).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2015</start_date>
  <completion_date type="Anticipated">June 23, 2018</completion_date>
  <primary_completion_date type="Actual">June 23, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of patients having a viral load &lt;50 copies/ml in each arm at week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>between Week 4 and Week 48</time_frame>
    <description>Percentage of patients having a confirmed viral load &gt; 50 copies/ml between week 4 and week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta CD 4</measure>
    <time_frame>until Week 48</time_frame>
    <description>delta CD4 in each arms from Baseline to W48, comparison between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual activation measures (sub study)</measure>
    <time_frame>Week 24</time_frame>
    <description>CD4+CD38+DR+, CD8+CD38+DR+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual activation marker measures (sub study)</measure>
    <time_frame>Week 24</time_frame>
    <description>sCD14, sCD163,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory cytokins measures (sub study)</measure>
    <time_frame>Week 24</time_frame>
    <description>TNFα, IFNγ, IL6, IP-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker measures (sub study)</measure>
    <time_frame>Week 24</time_frame>
    <description>CRPus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virus genotype</measure>
    <time_frame>Until Week 48</time_frame>
    <description>Evolution of viruses genotype profiles of patients who present a virologic failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA viral load (sub study)</measure>
    <time_frame>Week 24</time_frame>
    <description>RNA viral load in the genital tract (cervico-vaginal secretions or sperm): comparison between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV DNA evolution</measure>
    <time_frame>between day 0 and week 48</time_frame>
    <description>HIV DNA evolution in each arm from baseline to W48; comparison between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure predictive factors</measure>
    <time_frame>48 weeks</time_frame>
    <description>Determination of virological failure predictive factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the strategy on the acceptability and quality of life</measure>
    <time_frame>48 weeks</time_frame>
    <description>determination of quality of life with questionnary, comparison between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with an adverse event</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a severe adverse event</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance change</measure>
    <time_frame>48 weeks</time_frame>
    <description>Biological parameters evolution in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidic profiles</measure>
    <time_frame>48 weeks</time_frame>
    <description>Biological parameters evolution in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Clinical events with progression to AIDS or death. Proportion of individuals developing a new CDC-event (as defined by cdc 1993 classification) from baseline to week 48.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir 50mg +abacavir 600mg +lamivudine 300mg</intervention_name>
    <arm_group_label>triple therapy</arm_group_label>
    <other_name>Triumeq, EU/1/14/940/001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir</intervention_name>
    <arm_group_label>monotherapy</arm_group_label>
    <other_name>Tivicay , EU/1/13/892/001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1-infected patients with no previous AIDS event (excluding a healed tuberculosis);

          -  Current antiretroviral treatment associating dolutegravir + abacavir + lamivudine for
             at least 1 month;

          -  Nadir CD4 ≥ 100/mm3;

          -  Plasma RNA viral load &lt; 50 copies/ml for at least 12 months;

          -  Plasma RNA viral load &lt;20 or 40 copies/ml (according to the threshold of the method
             used by local laboratory) at the screening visit;

          -  No documented virologic failure or known resistance to any integrase inhibitor,

          -  Patient having provided a written consent;

          -  Patients follow-up possible in ambulatory;

          -  Patient age &gt; 18 years;

          -  Covered by health insurance

        Exclusion Criteria:

          -  Non-compliant patient

               -  Subject is pregnant, or lactating, or of childbearing potential and without
                  contraception;

               -  Active opportunistic infections (defining AIDS);

               -  Known hypersensibility to abacavir or lamivudine or dolutegravir;

               -  Patients harboring HLA B*5701;

               -  Major overweight (BMI ≥ 40);

               -  Weight &lt;40 kg;

               -  Creatinine clearance &lt; 50ml/min;

               -  Cirrhosis or severe liver failure (factor V &lt; 50%);

               -  Life Prognosis threatened within 6 months;

               -  Circumstances that may impair judgment or understanding of the information given
                  to the patient;

               -  Co-medication with carbamazepin, oxcarbamazepin, fosphenytoïn, phenobarbital,
                  phenytoïn, primidon, St John's wort or dofetilid;

               -  Malabsorption syndromes;

               -  The following laboratory criteria:

                    -  Serum AST,ALT &gt; 5 x upper limit of normal (ULN)

                    -  Thrombocytopenia with platelet count &lt; 50.000/ml

                    -  Anemia with hemoglobin &lt; 8g/dl

                    -  Polynuclear neutrophil count &lt; 500/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HOCQUELOUX Laurent</last_name>
    <role>Study Director</role>
    <affiliation>CHR d'ORLEANS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DESPUJOLS Aurélie</last_name>
    <phone>33 2 38 74 40 71</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>THOMAS Gaëlle</last_name>
    <phone>33 2 38 61 34 49</phone>
    <email>gaêlle.thomas@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHD de VENDEE</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ESNAULT Jean Luc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de LA ROCHELLE</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>RONCATO-SABERAN Mariam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>RAFFI François</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de NIORT</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DOS SANTOS Anabele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'ORLEANS</name>
      <address>
        <city>Orleans</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PRAZUCK Thierry</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HOCQUELOUX Laurent</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de POITIERS</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>LE MOAL Gwenaël</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>REY David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>BERNARD Louis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de NANCY</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MAY Thierry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014 May 15;28(8):1193-202. doi: 10.1097/QAD.0000000000000243.</citation>
    <PMID>24556869</PMID>
  </reference>
  <reference>
    <citation>Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014 May;58(9):1297-307. doi: 10.1093/cid/ciu046. Epub 2014 Jan 22.</citation>
    <PMID>24457345</PMID>
  </reference>
  <reference>
    <citation>Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ; GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul;14(7):572-80. doi: 10.1016/S1473-3099(14)70736-4. Epub 2014 Apr 27.</citation>
    <PMID>24783988</PMID>
  </reference>
  <reference>
    <citation>Prazuck T, Zucman D, Avettand-Fènoël V, Ducasse E, Bornarel D, Mille C, Rouzioux C, Hocqueloux L. Long-term HIV-1 virologic control in patients on a dual NRTI regimen. HIV Clin Trials. 2013 May-Jun;14(3):120-6. doi: 10.1310/hct1403-120.</citation>
    <PMID>23835514</PMID>
  </reference>
  <reference>
    <citation>Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255.</citation>
    <PMID>22180523</PMID>
  </reference>
  <reference>
    <citation>Calin R, Paris L, Simon A, Peytavin G, Wirden M, Schneider L, Valantin MA, Tubiana R, Agher R, Katlama C. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy. Antivir Ther. 2012;17(8):1601-4. doi: 10.3851/IMP2344. Epub 2012 Sep 3.</citation>
    <PMID>22941896</PMID>
  </reference>
  <reference>
    <citation>Monteiro P, Perez I, Laguno M, Martínez-Rebollar M, González-Cordon A, Lonca M, Mallolas J, Blanco JL, Gatell JM, Martínez E. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother. 2014 Mar;69(3):742-8. doi: 10.1093/jac/dkt406. Epub 2013 Oct 14.</citation>
    <PMID>24128667</PMID>
  </reference>
  <reference>
    <citation>Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, Molina JM, Hoen B, Pakianather S, Peytavin G, Marcelin AG, Flandre P. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010 Sep 24;24(15):2365-74. doi: 10.1097/QAD.0b013e32833dec20.</citation>
    <PMID>20802297</PMID>
  </reference>
  <reference>
    <citation>Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944.</citation>
    <PMID>20010070</PMID>
  </reference>
  <reference>
    <citation>Greig SL, Deeks ED. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6. Review. Erratum in: Drugs. 2015 Apr;75(5):561.</citation>
    <PMID>25698454</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 infected patient</keyword>
  <keyword>monotherapy</keyword>
  <keyword>dolutegravir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

